Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Tanaka, Tomotaka ^a   Sugiyama, Shinichiro ^a   Goishi, Hirokazu ^a   Kajihara, Tsuyoshi ^a   Akagi, Morihisa ^a   Miura, Toshio ^a  

^a Akitsu Prefectural Hospital   (Japan)

Author keywords

Adolescent; Adsorptive granulocyte and monocyte apheresis; Monotherapy; Myeloid lineage leucocyte; Paediatric inflammatory bowel disease; Prednisolone; Ulcerative colitis

Indexed keywords

MESALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; APHERESIS; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COLONOSCOPY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; FEMALE; GRANUCLOCYTE MONOCYTE ADSORPTION; HUMAN; LOW DRUG DOSE; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT SAFETY; RELAPSE; REMISSION; SCHOOL CHILD; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD COMPONENT REMOVAL; CHILD; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTES; HUMANS; MALE; MESALAMINE; MONOCYTES; PREDNISOLONE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SULFASALAZINE; TREATMENT FAILURE; YOUNG ADULT;

EID: 84882984520     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-130     Document Type: Article

References (32)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002, 347:417-419. 10.1056/NEJMra020831, 12167685.
2. Kornbluth A, Marion JF, Salomon P, Janowitz HD. How effective is current medical therapy for severe ulcerative colitis?. J Clin Gastroenterol 1995, 20:280-284. 10.1097/00004836-199506000-00004, 7665814.
3. Taffet SL, Das KM. Sulphasalazine-adverse effects and desensitization. Dig Dis Sci 1983, 28:833-842. 10.1007/BF01296907, 6136396.
4. Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000, 6:48-57. 10.1097/00054725-200002000-00009, 10701150.
5. Truelove SC, Jewell DP. Intensive intravenous regimens for severe attacks of ulcerative colitis. Lancet 1974, 1:1067-1070.
6. Ezri J, Marques-Vidal P, Nydegger A. Impact of disease and treatments on growth and puberty of pediatric patients with inflammatory bowel disease. Digestion 2012, 85:308-3019. 10.1159/000336766, 22688404.
7. Brown SL, Greene MH, Gershon SK, Edwards ET, Mraun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002, 46:3151-3158. 10.1002/art.10679, 12483718.
8. de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:981-998.
9. Belge KU, Ziegler-Heitbrock HW. The proinflammatory CD14 + CD16+ monocytes are a major source of TNF. J Immunol 2002, 168:3536-3542.
10. Hanai H, Iida T, Takeuchi K. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol 2008, 103:1210-1216. 10.1111/j.1572-0241.2007.01714.x, 18177452.
11. McCarthy DA, Rampton DS, Liu Y-C. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 1991, 86:489-493. 10.1111/j.1365-2249.1991.tb02958.x, 1554212, 1684141.
12. Nikolaus S, Bauditz J, Gionchetti P. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 1998, 42:470-476. 10.1136/gut.42.4.470, 1727082, 9616306.
13. Tibble JA, Sigthorsson G, Bridger D, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000, 119:15-22. 10.1053/gast.2000.8523, 10889150.
14. Saniabadi AR, Hanai H, Sawada K, Adachi T, Bjarnason I, Lofberg R, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003, 7:48-59. 10.1046/j.1526-0968.2003.00012.x, 12921115.
15. Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Bjarnason I, Lofberg R, et al. Therapeutic Leucocytapheresis for inflammatory bowel disease. Transf Apher Sci 2007, 37:191-200.
16. Yokoyama Y, Fukunaga K, Fukuda Y, Tozawa K, Kamikozuru K, Ohnishi K, et al. Demonstration of low-regulatory CD25HighCD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci 2007, 52:2725-2731. 10.1007/s10620-006-9560-z, 17404876.
17. Yamamoto T, Umegae S, Matsumoto K. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. J Crohn's Colitis 2012, 6:750-755. 10.1016/j.crohns.2011.12.009, 23962154.
18. Domenech E, Hinojosa J, Esteve-Comas M. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004, 20:1347-1352. 10.1111/j.1365-2036.2004.02288.x, 15606397.
19. Caprilli R, D'Ovidio V. Leukocytapheresis as promising therapy for inflammatory bowel disease. Dig Liver Dis 2007, 39:435-437. 10.1016/j.dld.2007.02.003, 17379590.
20. Panés J, Guilera M, Ginard D, Hinojosa J, González-Carro P, González-Lara V, et al. Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective?. Dig Liver Dis 2007, 39:617-625. 10.1016/j.dld.2007.03.007, 17531555.
21. Maiden L, Takeuchi K, Bjarnason I, et al. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis 2008, 14:1413-1418. 10.1002/ibd.20505, 18521900.
22. Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liver Dis 2007, 39:430-434. 10.1016/j.dld.2007.01.001, 17379588.
23. Rachmilewitz D on behalf of an international study group Coated mesalazine (5-aminisalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989, 298:82-86. Rachmilewitz D on behalf of an international study group.
24. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987, 92:1894-1898.
25. Tanaka T, Okanobu H, Kuga Y, Yoshifuku Y, Fujino H, Miwata T, et al. Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol 2010, 34:687-695. 10.1016/j.gcb.2010.08.007, 20934287.
26. Kashiwagi N, Saniabadi A, Shimoyama T. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002, (47):1334-1341.
27. Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective neutrophil and monocyte adsorptive apheresis as a first line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004, 49:565-571.
28. Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, et al. Adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis 2008, 40:731-736. 10.1016/j.dld.2008.02.012, 18387860.
29. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008, 135:400-409. 10.1053/j.gastro.2008.04.023, 18602921.
30. Suzuki Y, Yoshimura N, Saito Y, Saniabadi A. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006, 51:2031-2038. 10.1007/s10620-006-9199-9, 17004123.
31. Yokoyama Y, Kawai M, Fukunaga K, Kamikozuru K, Nagase K, Nogami K, et al. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol 2013, 13:27. 10.1186/1471-230X-13-27, 3583683, 23399416.
32. Mayberry JF, Lobo A, Ford AC, Thomas A. On behalf of the Guideline Development Group. NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people. Aliment Pharmacol Ther 2013, 37:195-203. 10.1111/apt.12102, 23151246.